Rational protein design: Developing next-generation biological therapeutics and nanobiotechnological tools

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 3, 2015, Pages 330-341

  Wilson, Corey J ^a,b  

^a Yale University   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINS; RECOMBINANT PROTEINS;

BIOLOGICAL METRICS; BIOLOGICAL THERAPEUTICS; COMPUTATIONAL PROTEIN DESIGN; LABORATORY METHODS; PERSONALIZED MEDICINES; PROTEIN STRUCTURES; PROTEIN THERAPEUTICS; REGULATORY FUNCTIONS;

SCAFFOLDS (BIOLOGY);

CATALYTIC ANTIBODY; IMMUNOSUPPRESSIVE AGENT; ORGANOPHOSPHATE; RECOMBINANT DNA; RECOMBINANT PROTEIN; NANOCAPSULE;

ANTIBODY COMBINING SITE; BASOPHIL; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CATALYSIS; CELIAC DISEASE; DIAGNOSTIC PROCEDURE; DNA REPAIR; DRUG DESIGN; ENZYME ACTIVITY; GENE TARGETING; GENE THERAPY; HUMAN; MACROMOLECULE; MAST CELL; NANOBIOTECHNOLOGY; NANODEVICE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; GENETICS; NANOMEDICINE; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; DRUG DESIGN; HUMANS; NANOCAPSULES; NANOMEDICINE; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84927158354     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1310     Document Type: Review

References (64)

1. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7:21-39.
2. Bradley P, Misura KMS, Baker D. Toward high-resolution de novo structure prediction for small proteins. Science 2005, 309:1868-1871.
3. Dahiyat BI, Gordon DB, Mayo SL. Automated design of the surface positions of protein helices. Protein Sci 1997, 6:1333-1337.
4. Dahiyat BI, Mayo SL. Protein design automation. Protein Sci 1996, 5:895-903.
5. Dahiyat BI, Mayo SL. De novo protein design: fully automated sequence selection. Science 1997, 278:82-87.
6. Dahiyat BI, Mayo SL. Probing the role of packing specificity in protein design. Proc Natl Acad Sci USA 1997, 94:10172-10177.
7. Dahiyat BI, Meade TJ, Mayo SL. Site-specific modification of α-helical peptides with electron donors and acceptors. Inorg Chim Acta 1996, 243:207-212.
8. Dahiyat BI, Sarisky CA, Mayo SL. De novo protein design: towards fully automated sequence selection. J Mol Biol 1997, 273:789-796.
9. Jiang L, Althoff EA, Clemente FR, Doyle L, Rothlisberger D, Zanghellini A, Gallaher JL, Betker JL, Tanaka F, Barbas CF, et al. De novo computational design of retro-aldol enzymes. Science 2008, 319:1387-1391.
10. Korkegian A, Black ME, Baker D, Stoddard BL. Computational thermostabilization of an enzyme. Science 2005, 308:857-860.
11. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D. Design of a novel globular protein fold with atomic-level accuracy. Science 2003, 302:1364-1368.
12. Schueler-Furman O, Wang C, Bradley P, Misura K, Baker D. Progress on modeling of protein structures and interactions. Science 2005, 310:638-642.
13. Howell SC, Inampudi KK, Bean DP, Wilson CJ. Understanding thermal adaptation of enzymes through the multistate rational design and stability prediction of 100 adenylate kinases. Structure 2014, 22:218-229.
14. Sivey JD, Howell SC, Bean DJ, McCurry DL, Mitch WA, Wilson CJ. Role of lysine during protein modification by HOCl and HOBr: halogen-transfer agent or sacrificial antioxidant? Biochemistry 2013, 52:1260-1271.
15. Gordon SR, Stanley EJ, Wolf S, Toland A, Wu SJ, Hadidi D, Mills JH, Baker D, Pultz IS, Siegel JB. Computational design of an α-gliadin peptidase. J Am Chem Soc 2012, 134:20513-20520.
16. Privett HK, Kiss G, Lee TM, Blomberg R, Chica RA, Thomas LM, Hilvert D, Houk KN, Mayo SL. Iterative approach to computational enzyme design. Proc Natl Acad Sci USA 2012, 109:3790-3795.
17. Rothlisberger D, Khersonsky O, Wollacott AM, Jiang L, DeChancie J, Betker J, Gallaher JL, Althoff EA, Zanghellini A, Dym O, et al. Kemp elimination catalysts by computational enzyme design. Nature 2008, 453:190-194.
18. Siegel JB, Zanghellini A, Lovick HM, Kiss G, Lambert AR, Clair JLS, Gallaher JL, Hilvert D, Gelb MH, Stoddard BL, et al. Computational design of an enzyme catalyst for a stereoselective bimolecular diels-alder reaction. Science 2010, 329:309-313.
19. Ohbu S, Yamashina A, Takasu N, Yamaguchi T, Murai T, Nakano K, Matsui Y, Mikami R, Sakurai K, Hinohara S. Sarin poisoning on Tokyo subway. South Med J 1997, 90:587-593.
20. Yokoyama K, Araki S, Murata K, Nishikitani M, Okumura T, Ishimatsu S, Takasu N. A preliminary study on delayed vestibulocerebellar effects of Tokyo subway sarin poisoning in relation to gender difference: frequency analysis of postural sway. J Occup Environ Med 1998, 40:17-21.
21. Newmark J. Nerve agents. Neurologist 2007, 13:20-32.
22. Millard CB, Lockridge O, Broomfield CA. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 1998, 37:237-247.
23. Gunnell D, Eddleston M, Phillips MR, Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health 2007, 7:357.
24. Gray AP. Design and structure-activity-relationships of antidotes to organo-phosphorus anticholinesterase agents. Drug Metab Rev 1984, 15:557-589.
25. Doctor BP, Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005, 157:167-171.
26. Hemmert AC, Otto TC, Chica RA, Wierdl M, Edwards JS, Lewis SM, Edwards CC, Tsurkan L, Cadieux CL, Kasten SA, et al. Nerve agent hydrolysis activity designed into a human drug metabolism enzyme. PLoS One 2011, 6:e17441.
27. Redinbo MR, Potter PM. Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today 2005, 10:313-325.
28. Cherny I, Greisen P Jr, Ashani Y, Khare SD, Oberdorfer G, Leader H, Baker D, Tawfik DS. Engineering V-type nerve agents detoxifying enzymes using computationally focused libraries. ACS Chem Biol 2013, 8:2394-2403.
29. Ashani Y, Goldsmith M, Leader H, Silman I, Sussman JL, Tawfik DS. In vitro detoxification of cyclosarin in human blood pre-incubated ex vivo with recombinant serum paraoxonases. Toxicol Lett 2011, 206:24-28.
30. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002, 2:647-655.
31. Choulika A, Perrin A, Dujon B, Nicolas JF. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol Cell Biol 1995, 15:1968-1973.
32. Gloor GB, Nassif NA, Johnson-Schlitz DM, Preston CR, Engels WR. Targeted gene replacement in Drosophila via P element-induced gap repair. Science 1991, 253:1110-1117.
33. Donoho G, Jasin M, Berg P. Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. Mol Cell Biol 1998, 18:4070-4078.
34. Smih F, Rouet P, Romanienko PJ, Jasin M. Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. Nucleic Acids Res 1995, 23:5012-5019.
35. Cohen-Tannoudji M, Robine S, Choulika A, Pinto D, El Marjou F, Babinet C, Louvard D, Jaisser F. I-SceI-induced gene replacement at a natural locus in embryonic stem cells. Mol Cell Biol 1998, 18:1444-1448.
36. Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003, 300:764.
37. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008, 26:808-816.
38. Thyme SB, Boissel SJ, Arshiya Quadri S, Nolan T, Baker DA, Park RU, Kusak L, Ashworth J, Baker D. Reprogramming homing endonuclease specificity through computational design and directed evolution. Nucleic Acids Res 2013, 42:2564-2576.
39. Boissel S, Jarjour J, Astrakhan A, Adey A, Gouble A, Duchateau P, Shendure J, Stoddard BL, Certo MT, Baker D, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 2013, 42:2591-2601.
40. Li T, Huang S, Zhao X, Wright DA, Carpenter S, Spalding MH, Weeks DP, Yang B. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 2011, 39:6315-6325.
41. Bandaria JN, Dutta S, Hill SE, Kohen A, Cheatum CM. Fast enzyme dynamics at the active site of formate dehydrogenase. J Am Chem Soc 2008, 130:22-23.
42. Bandaria JN, Cheatum CM, Kohen A. Examination of enzymatic H-tunneling through kinetics and dynamics. J Am Chem Soc 2009, 131:10151-10155.
43. Fields PA. Review: protein function at thermal extremes: balancing stability and flexibility. Comp Biochem Phys A 2001, 129:417-431.
44. Henzler-Wildman KA, Lei M, Thai V, Kerns SJ, Karplus M, Kern D. A hierarchy of timescales in protein dynamics is linked to enzyme catalysis. Nature 2007, 450:913-927.
45. Pena MI, Davlieva M, Bennett MR, Olson JS, Shamoo Y. Evolutionary fates within a microbial population highlight an essential role for protein folding during natural selection. Mol Syst Biol 2010, 6:1-11.
46. Wolf-Watz M, Thai V, Henzler-Wildman K, Hadjipavlou G, Eisenmesser EZ, Kern D. Linkage between dynamics and catalysis in a thermophilic-mesophilic enzyme pair. Nat Struct Mol Biol 2004, 11:945-949.
47. Zeng T, Wilson CJ, Mitch WA. Effect of chemical oxidation on the sorption tendency of dissolved organic matter to a model hydrophobic surface. Environ Sci Technol 2014, 48:5118-5126.
48. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov 2011, 10:655-656.
49. Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, Chen H, Phung S, Muchhal US, Horton HM, et al. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. MAbs 2013, 5:384-396.
50. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunology 2007, 7:715-725.
51. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
52. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007, 7:365-378.
53. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
54. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr, for the TNX-901 Peanut Allergy Study Group. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348:986-993.
55. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
56. Kinet JP. A new strategy to counter allergy. N Engl J Med 2005, 353:310-312.
57. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005, 11:446-449.
58. Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb. Immunol Lett 2012, 143:34-43.
59. Shabat D, Rader C, List B, Lerner RA, Barbas CF 3rd. Multiple event activation of a generic prodrug trigger by antibody catalysis. Proc Natl Acad Sci USA 1999, 96:6925-6930.
60. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G, Zhao K, Briscoe RJ, Almonte R, Woods JH, et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 1998, 95:10176-10181.
61. Yang G, Chun J, ArakawaUramoto H, Wang X, Gawinowicz MA, Zhao K, Landry DW. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J Am Chem Soc 1996, 118:5881-5890.
62. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science 1986, 234:1566-1570.
63. Meyer S, Ramot R, Kishore Inampudi K, Luo B, Lin C, Amere S, Wilson CJ. Engineering alternate cooperative-communications in the lactose repressor protein scaffold. Protein Eng Des Sel 2013, 26:433-443.
64. Tobin PH, Wilson CJ. Examining photoinduced energy transfer in Pseudomonas aeruginosa azurin. J Am Chem Soc 2014, 136:1793-1802.